NCT05562869View on ClinicalTrials.gov

Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplantation in Patients With Early Graft Dysfunction

PHASE3RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 3, 2024

Primary Completion Date

May 3, 2027

Study Completion Date

May 3, 2027

Conditions
Chronic Kidney Failure
Interventions
DRUG

Belatacept 250 Milligram Intravenous Powder for Solution

"Phase 1 (from 3 to 12 months post transplantation): conversion to belatacept (IV, 5mg/Kg days 1, 15,30, 45, 60 then every months) and CNI withdrawal.~Phase 2 (from 12 to 18 months post transplantation) : belatacept arrest and CNI resumption (tacrolimus target 6 ng/ml)"

Trial Locations (1)

44093

RECRUITING

CHU Nantes, Nantes

All Listed Sponsors
lead

Nantes University Hospital

OTHER